Free fatty acid receptors: emerging targets for treatment of diabetes and its complications
Vangaveti, Venkat, Shashidhar, Venkatesh, Jarrod, Ghassan, Baune, Bernhard T., and Kennedy, R. Lee (2010) Free fatty acid receptors: emerging targets for treatment of diabetes and its complications. Therapeutic Advances in Endocrinology and Metabolism, 1 (4). pp. 165-175.
|PDF (Published Version) - Repository staff only - Requires a PDF viewer such as GSview, Xpdf or Adobe Acrobat Reader|
View at Publisher Website: http://dx.doi.org/10.1177/20420188103810...
Fatty acids (FAs) are important as metabolic substrates and as structural components of biological membranes. However, they also function as signalling molecules. Recently, a series of G protein-coupled receptors (GPRs) for FAs has been described and characterized. These receptors have differing specificities for FAs of differing chain length and degree of saturation, for FA derivatives such as oleoylethanolamide, and for oxidized FAs. They are a critical component of the body’s nutrient sensing apparatus, and small molecule agonists and antagonists of these receptors show considerable promise in the management of diabetes and its complications. Agonists of the long-chain free fatty acid receptors FFAR1 and GPR119 act as insulin secretagogues, both directly and by increasing incretins. Although, drugs acting at short-chain FFA receptors (FFAR2 and FFAR3) have not yet been developed, they are attractive targets as they regulate nutrient balance through effects in the intestine and adipose tissue. These include regulation of the secretion of cholecystokinin, peptide YY and leptin. Finally, GPR132 is a receptor for oxidized FAs, which may be a sensor of lipid overload and oxidative stress, and which is involved in atherosclerosis. Regulation of its signalling pathways with drugs may decrease the macrovascular risk experienced by diabetic patients. In summary, FA receptors are emerging drug targets that are involved in the regulation of nutrient status and carbohydrate tolerance, and modulators of these receptors may well figure prominently in the next generation of antidiabetic drugs.
|Item Type:||Article (Refereed Research - C1)|
|Keywords:||atherosclerosis; diabetes; drug therapies; free fatty acid; G protein-coupled receptor|
|FoR Codes:||11 MEDICAL AND HEALTH SCIENCES > 1117 Public Health and Health Services > 111716 Preventive Medicine @ 100%|
|SEO Codes:||92 HEALTH > 9204 Public Health (excl. Specific Population Health) > 920411 Nutrition @ 100%|
|Deposited On:||11 Oct 2010 13:39|
|Last Modified:||12 Feb 2011 20:59|
Last 12 Months: 0
|Citation Counts with External Providers:|
Repository Staff Only: item control page